AlphAIAlphAI — Financial news for AI agents
investing.comSEP 172 min read$ABBV

AbbVie to present phase 3 etentamig data at myeloma meeting

AbbVie (NYSE:ABBV) will present Phase 3 data on etentamig, a BCMA x CD3 bispecific T-cell engager, at the 23rd International Myeloma Society Annual Meeting. The CERVINO study met primary endpoints, showing significant improvements in objective response rate and progression-free survival in relapsed/refractory multiple myeloma. The company will also present data on investigational assets ABBV-2001 and surzetoclax. Presentations are scheduled for September 25-26, 2026.

Original reporting
investing.com
Published Sep 17, 2026, 1:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 3:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$ABBV
Bullish
high confidence
Mentioned
$ABBV
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

The Phase 3 data positions etentamig as a potential new therapy for relapsed/refractory multiple myeloma, influencing future revenue forecasts.

02

Market read

First‑report positive trial data for a major biotech, likely to move the stock and related sector.

03

What to watch

Potential competition from other bispecifics and the need for FDA filing timelines.

Relevance 9/10Novelty 9/10Timing: today

Background

AbbVie is a large U.S. biopharma company with a pipeline of immuno‑oncology agents.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie announced positive Phase 3 CERVINO trial results for etentamig, showing statistically significant improvements in response rate and progression‑free survival.

Expected impact

Potential short‑term upside of 5‑10% as investors price in a future launch.

Evidence & confidence

Phase 3 success is a material catalyst for a large biotech; market typically reacts strongly to such data.

Market effects

Sector

Positive myeloma data could lift other BCMA‑targeted biotech stocks.

Regional

U.S. biotech sector may see modest gains.

Global

International investors tracking oncology pipelines will note the result.

Counterpoint

What could challenge this read

If regulatory scrutiny intensifies or data is not replicated, the rally could be short‑lived.

Key entities

  • Company
    AbbVie

    U.S. biopharma developing etentamig.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 17
$ABBVMed

Atogepant associated with reduced menstrual migraine days

AbbVie's atogepant (Qulipta) showed significant reductions in menstrual migraine days in a Phase 3 study. Patients saw a 1.2-day reduction vs. 0.4 days for placebo. The study met all secondary endpoints, including headache days and functional disability. AbbVie plans to assess long-term effects in an extension study. No new safety concerns were reported.

healio.com2 min
SEP 17
$ABBVMedAI 8/10

AbbVie Targets Dry Eye Market Upside With New ABBV

AbbVie (ABBV) completed a clinical trial for its dry eye treatment ABBV-444, comparing it to Refresh Optive UD. The study, which lasted 90 days, aims to show similar or better symptom relief and safety. Positive results could support a new revenue stream for AbbVie in the growing dry eye market.

tipranks.com2 min
SEP 17
$ABBVHighAI 9/10

AbbVie To Present Positive Phase 3 Etentamig Data At IMS 2026

AbbVie (ABBV) will present Phase 3 results for Etentamig, its investigational multiple myeloma treatment, at the 2026 IMS Annual Meeting. The CERVINO study met primary endpoints, showing significant improvements in ORR and PFS. AbbVie also plans to share data on its broader myeloma pipeline, including ABBV-2001 and Surzetoclax. ABBV stock closed at $262.51, up 0.27% in pre-market trading.

rttnews.com2 min
SEP 16
$ABBVMedAI 8/10

How AbbVie's Neuroscience Portfolio Has Transformed Over the Years

AbbVie's neuroscience portfolio has expanded significantly, now including migraine and Parkinson’s disease treatments alongside its traditional psychiatry and neurotoxin therapies. The portfolio generated $6.1B in H1 2026, up 21.8% YoY, with broad-based growth across psychiatry, migraine, and PD. AbbVie raised its full-year outlook to $12.7B, citing strong performance from Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, and Vyalev. The company also anticipates a potential FDA decision on tavapadon

tradingview.com3 min
SEP 15
$ABBVMedAI 8/10

AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline

AbbVie (NYSE: ABBV) is focusing on post-HUMIRA growth through the Apogee deal and its immunology pipeline. The company reported strong Phase 2b data for Apogee and aims to expand in atopic dermatitis and asthma markets. AbbVie expects a Q4 approval for SKYRIZI in Crohn's disease and additional catalysts for RINVOQ. The company is also developing combination therapies and exploring neuroscience and oncology opportunities, including VYALEV and etentamig.

yahoo.com3 min